Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HiV1- Positive Clear all
Completed Phase 3 Interventional Results available

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551
View directory record Official record
Conditions
HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
56
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 2 Interventional

A Study of T-20 in HIV-Positive Adults

NCT00002228
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Trimeris
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

NCT01815736
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 2 Interventional

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

NCT00002235
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
13 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

NCT00000952
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 2 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
12
States / cities
Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

NCT03446573
View directory record Official record
Conditions
HIV Infections
Interventions
DTG + 3TC, TAF based regimen (TBR)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
54
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Early Phase 1 Interventional

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

NCT01836068
View directory record Official record
Conditions
HIV
Interventions
Enfuvirtide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

NCT00051831
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

NCT02345252
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 9, 2026, 7:31 PM EDT
Not listed Phase 1 Interventional

A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

NCT00006209
View directory record Official record
Conditions
HIV Infections
Interventions
Tucaresol
Drug
Lead sponsor
Aaron Diamond AIDS Research Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

NCT01818596
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 9, 2026, 7:31 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

NCT00000890
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Not applicable Interventional

A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

NCT00000895
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Nelfinavir mesylate, Nevirapine, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

NCT00270465
View directory record Official record
Conditions
HIV
Interventions
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

NCT00002361
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss

NCT00000925
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Optimune oral nutritional supplement
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Not applicable Interventional

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

NCT00000896
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
San Diego, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Not applicable Interventional

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

NCT00002354
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial

NCT01177059
View directory record Official record
Conditions
HIV-1
Interventions
OZ1 transduced cells
Genetic
Lead sponsor
Janssen-Cilag Pty Ltd
Industry
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 9, 2026, 7:31 PM EDT
Completed Phase 4 Interventional

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

NCT00005764
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 7:31 PM EDT